CLINICAL TRIALS PROFILE FOR FLUOROMETHOLONE
✉ Email this page to a colleague
All Clinical Trials for fluorometholone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00707421 ↗ | Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes | Completed | Funding for Research in Ophthalmology (FRO) | Phase 3 | 2005-07-01 | Antiglaucoma medication have been shown to induce subclinical conjunctival inflammation in a considerable proportion of glaucoma patients. Today, trabeculectomy still remains the gold standard as surgical treatment of medically uncontrolled glaucoma disease. However, this procedure is associated with variable possible complications, of which subconjunctival fibrosis is the most frequent one. The latter results in a non-functional filtering bleb. As a consequence, either additional interventions such as laser suture lysis, needling, bleb revision or additional IOP-lowering medication is necessary. Previous studies demonstrated a benefit of the use of topical steroids postoperatively in reducing inflammation and subsequent subconjunctival fibrosis. In this perspective, we will prospectively explore the usefulness of topical NSAID or corticosteroid therapy preoperatively as compared to placebo in subjects scheduled for first-time trabeculectomy, without interrupting topical antiglaucoma therapy. This will allow us to determine wether the impact of longterm topical antiglaucoma therapy on subclinical conjunctival inflammation which possibly result in postoperative fibrosis and bleb failure can be reversed by anti-inflammatory medication before filtering surgery. |
| NCT00707421 ↗ | Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes | Completed | Universitaire Ziekenhuizen Leuven | Phase 3 | 2005-07-01 | Antiglaucoma medication have been shown to induce subclinical conjunctival inflammation in a considerable proportion of glaucoma patients. Today, trabeculectomy still remains the gold standard as surgical treatment of medically uncontrolled glaucoma disease. However, this procedure is associated with variable possible complications, of which subconjunctival fibrosis is the most frequent one. The latter results in a non-functional filtering bleb. As a consequence, either additional interventions such as laser suture lysis, needling, bleb revision or additional IOP-lowering medication is necessary. Previous studies demonstrated a benefit of the use of topical steroids postoperatively in reducing inflammation and subsequent subconjunctival fibrosis. In this perspective, we will prospectively explore the usefulness of topical NSAID or corticosteroid therapy preoperatively as compared to placebo in subjects scheduled for first-time trabeculectomy, without interrupting topical antiglaucoma therapy. This will allow us to determine wether the impact of longterm topical antiglaucoma therapy on subclinical conjunctival inflammation which possibly result in postoperative fibrosis and bleb failure can be reversed by anti-inflammatory medication before filtering surgery. |
| NCT00824811 ↗ | Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel | Withdrawn | Allergan | Phase 2 | 2009-06-01 | Objective: To evaluate the safety and efficacy of topical cyclosporine eye drops (Restasis®) for the treatment of epiphora caused by canalicular stenosis secondary to Docetaxel (Taxotere®) treatment for various cancers. |
| NCT00824811 ↗ | Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel | Withdrawn | M.D. Anderson Cancer Center | Phase 2 | 2009-06-01 | Objective: To evaluate the safety and efficacy of topical cyclosporine eye drops (Restasis®) for the treatment of epiphora caused by canalicular stenosis secondary to Docetaxel (Taxotere®) treatment for various cancers. |
| NCT01288404 ↗ | Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium | Completed | Ramathibodi Hospital | N/A | 2008-01-01 | Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence. |
| NCT01448213 ↗ | Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK) | Completed | Price Vision Group | Phase 2 | 2011-10-01 | The purpose of this study is to compare two different commonly used steroid dosing regimens after Descemet's membrane endothelial keratoplasty (DMEK) transplant surgery. The investigators hope to determine if one is more effective at preventing rejection or if both are equally effective. |
| NCT01562795 ↗ | Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease | Completed | Wenzhou Medical University | N/A | 2012-03-01 | This clinical trial is to investigate whether nonsteroid anti-inflammatory drops have therapeutic effect on moderate to severe dry eye patients.And compare the efficacy of the two nonsteroid anti-inflammatory drops with topical corticosteroids. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for fluorometholone
Condition Name
Clinical Trial Locations for fluorometholone
Trials by Country
Clinical Trial Progress for fluorometholone
Clinical Trial Phase
Clinical Trial Sponsors for fluorometholone
Sponsor Name
